# The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

> **NCT06046820** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Inozyme Pharma** · enrollment: 27 (actual)

## Conditions studied

- Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency
- Autosomal Recessive Hypophosphatemic Rickets
- Generalized Arterial Calcification of Infancy

## Interventions

- **DRUG:** INZ-701
- **DRUG:** Control Arm (Conventional Therapy)

## Key facts

- **NCT ID:** NCT06046820
- **Lead sponsor:** Inozyme Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-05
- **Primary completion:** 2026-01
- **Final completion:** 2026-02
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06046820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06046820, "The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06046820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*